Literature DB >> 14973800

The effect of intravenous quinaprilat on plasma cytokines and hemodynamic variables during cardiac surgery.

Myron M Kwapisz1, Matthias Müller, Ehrenfried Schindler, Selma Demir, Mirko Veit, Peter Roth, Gunter Hempelmann.   

Abstract

OBJECTIVES: Perioperative treatment with angiotensin-converting enzyme (ACE) inhibitors in cardiac surgery with cardiopulmonary bypass is still controversial. Using ACE inhibitors during cardiac surgery might be associated with an increased risk of critical hypotensive episodes. On the other hand, ACE inhibitors could have beneficial effects with respect to the development of the systemic inflammatory response syndrome.
DESIGN: The effect of acute administration of quinaprilat on hemodynamic variables and plasma cytokines was assessed under double-blind, randomized, and placebo-controlled conditions.
SETTING: Department of anesthesiology and cardiovascular surgery clinic in a university hospital. PARTICIPANTS: Forty patients without preexisting cardiac failure, undergoing coronary artery bypass grafting.
INTERVENTIONS: Patients received 0.08 mg/kg of intravenous quinaprilat or intravenous isotonic saline solution after induction of anesthesia. MEASUREMENTS AND
RESULTS: Blood samples were taken after induction of anesthesia (T0), before cardiopulmonary bypass (T1), at the end of surgery (T2), and 4 hours after the end of surgery (T3). There was no difference between the 2 groups regarding mean arterial pressure and inotropic or vasopressor support. Systemic vascular resistance index was significantly lower in the quinaprilat group at T2 (p = 0.016) and T3 (p = 0.017). No difference in proinflammatory cytokine levels was observed between the 2 groups.
CONCLUSIONS: The present investigation shows that acute administration of an intravenous ACE inhibitor, quinaprilat, has no influence on proinflammatory cytokines during cardiac surgery with cardiopulmonary bypass. The patients treated with quinaprilat showed an improved systemic vascular resistance index with no increased risk of deleterious hemodynamic episodes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14973800     DOI: 10.1053/j.jvca.2003.10.011

Source DB:  PubMed          Journal:  J Cardiothorac Vasc Anesth        ISSN: 1053-0770            Impact factor:   2.628


  5 in total

1.  Angiotensin-converting enzyme inhibition alters the inflammatory and fibrinolytic response to cardiopulmonary bypass in children.

Authors:  Gregory A Fleming; Frederic T Billings; Tom M Klein; David P Bichell; Karla G Christian; Mias Pretorius
Journal:  Pediatr Crit Care Med       Date:  2011-09       Impact factor: 3.624

2.  Acute kidney injury following surgical aortic valve replacement.

Authors:  Marc Najjar; Halit Yerebakan; Robert A Sorabella; Denis J Donovan; Alexander P Kossar; Sowmyashree Sreekanth; Paul Kurlansky; Michael A Borger; Michael Argenziano; Craig R Smith; Isaac George
Journal:  J Card Surg       Date:  2015-06-24       Impact factor: 1.620

3.  Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.

Authors:  Mias Pretorius; Katherine T Murray; Chang Yu; John G Byrne; Frederic T Billings; Michael R Petracek; James P Greelish; Steven J Hoff; Stephen K Ball; Vineet Mishra; Simon C Body; Nancy J Brown
Journal:  Crit Care Med       Date:  2012-10       Impact factor: 7.598

Review 4.  Perioperative angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers for preventing mortality and morbidity in adults.

Authors:  Zui Zou; Hong B Yuan; Bo Yang; Fengying Xu; Xiao Y Chen; Guan J Liu; Xue Y Shi
Journal:  Cochrane Database Syst Rev       Date:  2016-01-27

5.  Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.

Authors:  F T Billings; J M Balaguer; Yu C; P Wright; M R Petracek; J G Byrne; N J Brown; M Pretorius
Journal:  Clin Pharmacol Ther       Date:  2012-06       Impact factor: 6.875

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.